Regardless of a significant progress in understanding the link between TREX1 mutations and RVCL symptoms, there is still a need for a robust disease model to perform high throughput drug screenings; for example, FDA approved compound libraries assessment could help to prioritize the drug candidates. This evidence concerns the gene TREX1 and Retinal vasculopathy and cerebral leukodystrophy.